Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Newsfilter
Strategic Investment Announcement: Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, purchasing approximately 14.1 million shares to support the development of Alpha Tau's innovative cancer therapy technology, Alpha DaRT.
Collaboration Goals: The partnership aims to leverage Oramed's expertise in capital markets and business strategy to accelerate Alpha Tau's clinical trials, manufacturing expansion, and commercialization efforts, while also enhancing governance through board appointments.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ORMP with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ORMP
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
Continue Reading
Oramed Pharmaceuticals Receives $18 Million Payment, Declares $0.25 Dividend
- Significant Investment Returns: Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, bringing total returns on its $99.5 million investment to $118 million, demonstrating the company's success in investment management and profitability.
- Debt Structure Optimization: Oramed retains a $27 million note and a $12 million convertible note, which can be converted into Scilex equity at $36 per share, ensuring potential capital appreciation in the future.
- Shareholder Reward Plan: The company's board approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, aimed at rewarding shareholders and enhancing investor confidence.
- Funding Source Assurance: This dividend will be funded with surplus capital, reflecting Oramed's financial management robustness and confidence in future investments.
Continue Reading